This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 7 of 103 for:    fibromyalgia | Recruiting, Not yet recruiting, Available Studies | Interventional Studies

Repetitive Thoughts in Fibromyalgia: Impact of Rumination on the Emotional and Cognitive Dimensions of Fibromyalgia (PRFM-1)

This study is currently recruiting participants.
See Contacts and Locations
Verified April 2017 by Centre Hospitalier Universitaire, Amiens
Sponsor:
Information provided by (Responsible Party):
Centre Hospitalier Universitaire, Amiens
ClinicalTrials.gov Identifier:
NCT03133455
First received: April 4, 2017
Last updated: April 27, 2017
Last verified: April 2017
  Purpose

Dysfunctional chronic diffuse pain syndrome, concerning 2% of the French population, Fibromyalgia (FM) is classified either as a psychological disease or as a somatic disease. This dichotomous reasoning does not lead to a better understanding and does not allow the use or development of new psychological tools of care.

The issue of the proximity between FM and depression highlighted by some authors and the presence of anxious comorbidities may arise at a different level, that of the transdiagnostic approach. Rumination is one of these transdiagnostic processes that are the subject of recent studies and one of the dimensions of which (abstract analytical rumination) is at work in depression and a number of psychopathologies. The investigator therefore wishes to explore the process of rumination and its abstract analytical dimension in FM and to explore its link with the depressive and anxious manifestations frequently associated with this disorder.


Condition Intervention
Fibromyalgia Other: Evaluate the link between an abstract / analytical thinking style and depressive manifestations in FM.

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Repetitive Thoughts in Fibromyalgia: Impact of Rumination on the Emotional and Cognitive Dimensions of Fibromyalgia

Resource links provided by NLM:


Further study details as provided by Centre Hospitalier Universitaire, Amiens:

Primary Outcome Measures:
  • Analyze the rate of rumination and depression of a fibromyalgia patient using a questionnaire [ Time Frame: 1 hour ]
    Analyze the rate of rumination and depression of a fibromyalgia patient using a questionnaire


Estimated Enrollment: 80
Actual Study Start Date: September 16, 2015
Estimated Study Completion Date: December 30, 2017
Estimated Primary Completion Date: December 30, 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Patient with Fibromyalgia Other: Evaluate the link between an abstract / analytical thinking style and depressive manifestations in FM.
Evaluate the link between an abstract / analytical thinking style and depressive manifestations in FM.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • FM Criteria of the American College of Rheumatology ACR 1990.
  • Major Patients
  • free and informed consent signed
  • stable treatment for at least one month
  • Native French speaker
  • Patient covered by health insurance.

Exclusion Criteria:

  • Patient deprived of liberty or protected major (under guardianship or curatorship)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT03133455

Contacts
Contact: Eric SERRA, Dr +33322668820 serra.eric@chu-amiens.fr

Locations
France
CHU Amiens Picardie Recruiting
Amiens, Picardie, France, 80054
Contact: Eric SERRA, Dr    +33322668820    serra.eric@chu-amiens.fr   
Sponsors and Collaborators
Centre Hospitalier Universitaire, Amiens
  More Information

Responsible Party: Centre Hospitalier Universitaire, Amiens
ClinicalTrials.gov Identifier: NCT03133455     History of Changes
Other Study ID Numbers: PI2015_843_0024
Study First Received: April 4, 2017
Last Updated: April 27, 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Centre Hospitalier Universitaire, Amiens:
Rumination

Additional relevant MeSH terms:
Fibromyalgia
Myofascial Pain Syndromes
Muscular Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Neuromuscular Diseases
Nervous System Diseases

ClinicalTrials.gov processed this record on August 18, 2017